Beyond Air Reports $34.3 Million Net Loss and $7.7 Million Revenue for Fiscal Year Ending March 31, 2026

Beyond Air, Inc. reported a net loss of $34.3 million for the fiscal year ending March 31, 2026, a decrease from the $48.5 million loss recorded in the previous year. The company generated revenues of $7.7 million, a significant increase from $3.7 million in the prior year, primarily driven by new hospital contracts and international market expansion. The cost of revenue also rose to $7.4 million, resulting in a gross profit of $0.3 million, compared to a gross loss of $1.7 million in the previous fiscal year. The reduction in losses and the increase in revenue reflect the company's ongoing efforts to commercialize its LungFit® PH system, which received FDA approval in June 2022 and CE mark approval in November 2024.

In terms of operational developments, Beyond Air has made strategic advancements, including the launch of its LungFit® PH system in the U.S. and the signing of distribution agreements in over 40 countries. The company has also initiated clinical trials for its product candidates targeting viral lung infections and nontuberculous mycobacteria (NTM) lung infections. As of March 31, 2026, Beyond Air employed 54 full-time staff, a number that reflects its focus on expanding its operational capabilities to support its commercialization efforts.

The company has faced challenges, including a substantial accumulated deficit of approximately $319.6 million since its inception. Beyond Air's financial stability is contingent on its ability to generate positive cash flows and secure additional funding, as indicated by its ongoing need for capital to support operations. The company has entered into a loan agreement for $13.5 million and has plans to raise additional funds through equity offerings. However, there is no assurance that such financing will be available on favorable terms, which raises concerns about its ability to continue as a going concern.

Looking ahead, Beyond Air anticipates continued net losses and cash outflows for at least the next twelve months. The company is focused on expanding the commercialization of its LungFit® PH system and advancing its product candidates through clinical trials. However, the success of these initiatives is uncertain and will depend on various factors, including regulatory approvals, market acceptance, and the competitive landscape. The company’s ability to manage its growth effectively and navigate the complexities of the medical device market will be critical to its future success.